Stock Quote
Cephalon, Inc. (CEPH.O) (Nasdaq)
$55.23
1:00pm EST
-1.20%
$55.90
$54.44
970,247
$55.85
$54.70
$81.35
$52.55
0.48
3,244,202
CEPH.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Baldino, Frank | Chairman of the Board, Chief Executive Officer | 14,496,500 |
| Buchi, J. Kevin | Chief Financial Officer, Executive Vice President | 3,378,460 |
| Savini, Carl | Executive Vice President, Chief Administrative Officer | 3,387,820 |
Profile
Cephalon, Inc. is an international biopharmaceutical company engaged in the discovery, development and commercialization of products in three therapeutic areas: central nervous system (CNS), pain and oncology. In addition to conducting an active research and development program, the Company markets... Full Description
Company Address
Cephalon, Inc.
41 Moores Road
P.O. Box 4011
Frazer PA 19355
P: +1610.3440200
F: +1610.3440065
41 Moores Road
P.O. Box 4011
Frazer PA 19355
P: +1610.3440200
F: +1610.3440065
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Johnson & Johnson | $62.89 | -0.41 |
| GlaxoSmithKline plc | £1,279.00 | +7.00 |
| Bayer AG | €51.16 | -0.09 |
| CEPH.O | Industry | |
|---|---|---|
| P/E(TTM) | 16.86 | 12.96 |
| P/S(TTM) | 1.93 | 29.74 |
| ROI(TTM) | 8.24 | 2.44 |
| ROE(TTM) | 13.87 | 3.72 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 1.54 |
| EPS Est. (Current Year) | 5.96 |
| Total Revenue | $549.41M |
| Net Income | $95.10M |
| EPS | $1.31 |
